Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.6K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

597
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
597
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Structure and Function of Platelets01:18

Structure and Function of Platelets

4.6K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perceptions of motivating factors and barriers to precepting.

Journal of the American Association of Nurse Practitioners·2022
Same author

Using a Standardized Rounding Tool to Improve the Incidence of Spontaneous Awakening and Breathing Trials.

Critical care nurse·2022
Same author

Incorporating the Lived Experience Into Graduate Nursing Education.

The Journal of nursing education·2021
Same author

Improving Medical and Nurse Practitioner Student Confidence and Clinical Skill in Advance Care Plan Development: A Multidisciplinary Mentorship Model.

The American journal of hospice & palliative care·2021
Same author

Critical Care Considerations in Adult Patients With Influenza-Induced ARDS.

Critical care nurse·2020
Same author

Atrial fibrillation clinical decision aid for emergency medicine providers: An initiative to improve quality healthcare outcomes in adults with new-onset atrial fibrillation.

Heart & lung : the journal of critical care·2018

Related Experiment Video

Updated: Mar 25, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

Platelet Inhibitors.

Megan M Shifrin1, S Brian Widmar2

  • 1Vanderbilt University School of Nursing, 461 21st Avenue South, 382 Frist Hall, Nashville, TN 37240, USA.

The Nursing Clinics of North America
|February 22, 2016
PubMed
Summary

Platelet-inhibiting medications are crucial for acute coronary syndrome but lack a specific reversal agent. Platelet transfusions may help manage bleeding after their use.

Keywords:
Acute coronary syndromeAntiplateletBleedingNursingPlateletsThrombosis

More Related Videos

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.5K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.4K

Related Experiment Videos

Last Updated: Mar 25, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.5K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.4K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Antithrombotic medications are standard for acute coronary syndrome (ACS) management.
  • Platelet function (adhesion, activation, aggregation) is key to thrombosis.
  • Platelet-inhibiting drugs target these functions to reduce clot formation.

Purpose of the Study:

  • To review the role of platelet inhibitors in ACS.
  • To highlight the challenge of managing bleeding complications.
  • To discuss current strategies for reversing platelet inhibition.

Main Methods:

  • Literature review of antithrombotic therapies in ACS.
  • Analysis of platelet function and inhibition mechanisms.
  • Examination of bleeding management protocols.

Main Results:

  • Platelet inhibitors effectively reduce thrombosis in ACS.
  • Active bleeding is a contraindication for these drugs.
  • No specific reversal agent currently exists for platelet inhibitors.

Conclusions:

  • Platelet inhibitors are vital in ACS but pose bleeding risks.
  • Management of bleeding often relies on supportive measures.
  • Platelet transfusion is a potential option for active bleeding post-inhibition.